老年创伤性急性硬膜下血肿手术随机评估(RESET-ASDH试验):多中心平行组实用性随机对照试验研究方案
RESET-ASDH是一项国际多中心随机对照试验,计划从17家比利时和荷兰创伤中心招募300例≥65岁创伤性急性硬膜下血肿患者,随机分配至早期神经外科血肿清除术或初期保守治疗(可延迟二期手术),主要终点为1年时GOS-E功能结局,采用意向性分析。
要点
- 针对≥65岁创伤性急性硬膜下血肿患者,比较早期手术与初期保守治疗的成本效果。
- 计划招募300例,来自17家比利时和荷兰创伤中心,1:1随机分组。
- 主要终点为伤后1年GOS-E功能结局,按意向性分析。
核心结论
- 研究结果将在发表后实施并在国际会议上展示,根据试验结果,当前脑创伤基金会指南要么获得高质量证据支持,要么将被修改。
研究设计与样本
- 国际多中心实用性随机对照试验,采用平行组设计,计划从17家比利时和荷兰创伤中心招募300例患者。
- 纳入标准:年龄≥65岁,首次就诊时GCS≥9且创伤性急性硬膜下血肿>10 mm,或血肿<10 mm且中线移位>5 mm;或GCS<9且血肿<10 mm、中线移位<5 mm且无颅外原因解释昏迷状态,且存在临床均势。
- 随机分配至早期手术血肿清除或初期保守治疗(可延迟二期手术),神经外科技术由神经外科医生自行决定。
- 当无法在治疗时间窗内获得患者或代理人同意时,采用延迟同意程序入组;已获得荷兰和比利时医学伦理批准。
- 按意向性分析,主要终点为1年时GOS-E功能结局;患者招募于2022年开始,预计2024年结束。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rapidly increasing number of elderly (≥ 65 years old) with TBI is accompanied by substantial medical and economic consequences. An ASDH is the most common injury in elderly with TBI and the surgical versus conservative treatment of this patient group remains an important clinical dilemma. Current BTF guidelines are not based on high-quality evidence and compliance is low, allowing for large international treatment variation. The RESET-ASDH trial is an international multicenter RCT on the (cost-)effectiveness of early neurosurgical hematoma evacuation versus initial conservative treatment in elderly with a t-ASDH METHODS: In total, 300 patients will be recruited from 17 Belgian and Dutch trauma centers. Patients ≥ 65 years with at first presentation a GCS ≥ 9 and a t-ASDH > 10 mm or a t-ASDH < 10 mm and a midline shift > 5 mm, or a GCS < 9 with a traumatic ASDH < 10 mm and a midline shift < 5 mm without extracranial explanation for the comatose state, for whom clinical equipoise exists will be randomized to early surgical hematoma evacuation or initial conservative management with the possibility of delayed secondary surgery. When possible, patients or their legal representatives will be asked for consent before inclusion. When obtaining patient or proxy consent is impossible within the therapeutic time window, patients are enrolled using the deferred consent procedure. Medical-ethical approval was obtained in the Netherlands and Belgium. The choice of neurosurgical techniques will be left to the discretion of the neurosurgeon. Patients will be analyzed according to an intention-to-treat design. The primary endpoint will be functional outcome on the GOS-E after 1 year. Patient recruitment starts in 2022 with the exact timing depending on the current COVID-19 crisis and is expected to end in 2024. DISCUSSION: The study results will be implemented after publication and presented on international conferences. Depending on the trial results, the current Brain Trauma Foundation guidelines will either be substantiated by high-quality evidence or will have to be altered. TRIAL REGISTRATION: Nederlands Trial Register (NTR), Trial NL9012 . CLINICALTRIALS: gov, Trial NCT04648436 .
引用
- Singh RD, van Dijck JTJM, van Essen TA, et al. Randomized Evaluation of Surgery in Elderly with Traumatic Acute SubDural Hematoma (RESET-ASDH trial): study protocol for a pragmatic randomized controlled trial with multicenter parallel group design. Trials. 2022. PMID: 35351178. doi:10.1186/s13063-022-06184-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。